[go: up one dir, main page]

IN2014CN04809A - - Google Patents

Download PDF

Info

Publication number
IN2014CN04809A
IN2014CN04809A IN4809CHN2014A IN2014CN04809A IN 2014CN04809 A IN2014CN04809 A IN 2014CN04809A IN 4809CHN2014 A IN4809CHN2014 A IN 4809CHN2014A IN 2014CN04809 A IN2014CN04809 A IN 2014CN04809A
Authority
IN
India
Prior art keywords
tbut
prolongs
treatment
disclosed
dry eye
Prior art date
Application number
Inventor
Joseph G Vehige
Peter A Simmons
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47459152&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IN2014CN04809(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of IN2014CN04809A publication Critical patent/IN2014CN04809A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/716—Glucans
    • A61K31/717—Celluloses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/04—Artificial tears; Irrigation solutions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dispersion Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A salt free emulsion for the treatment of dry eye and other ocular conditions is disclosed which contains castor oil and does not contain olive oil which prolongs TBUT and provides superior comfort.
IN4809CHN2014 2011-12-07 2012-12-07 IN2014CN04809A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161568089P 2011-12-07 2011-12-07
US201261625401P 2012-04-17 2012-04-17
PCT/US2012/068615 WO2013086449A1 (en) 2011-12-07 2012-12-07 Efficient lipid delivery to human tear film using a salt-sensitive emulsion system

Publications (1)

Publication Number Publication Date
IN2014CN04809A true IN2014CN04809A (en) 2015-09-18

Family

ID=47459152

Family Applications (1)

Application Number Title Priority Date Filing Date
IN4809CHN2014 IN2014CN04809A (en) 2011-12-07 2012-12-07

Country Status (27)

Country Link
US (2) US20130150324A1 (en)
EP (5) EP3981387A1 (en)
JP (1) JP6142419B2 (en)
KR (1) KR102017922B1 (en)
CN (2) CN108969482A (en)
AR (1) AR089123A1 (en)
AU (2) AU2012347459A1 (en)
BR (1) BR112014013820A2 (en)
CA (1) CA2858574C (en)
CL (1) CL2014001518A1 (en)
CO (1) CO6990739A2 (en)
DK (2) DK2787969T3 (en)
ES (2) ES2797650T3 (en)
HU (2) HUE057140T2 (en)
IL (1) IL233008A (en)
IN (1) IN2014CN04809A (en)
MX (1) MX355216B (en)
MY (1) MY173378A (en)
PH (2) PH12014501296B1 (en)
PL (2) PL2787968T3 (en)
PT (2) PT2787968T (en)
RU (1) RU2014127074A (en)
SG (1) SG11201403013VA (en)
SI (2) SI2787969T1 (en)
TW (1) TWI652072B (en)
WO (2) WO2013086449A1 (en)
ZA (1) ZA201404228B (en)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye
US9907826B2 (en) 2011-12-07 2018-03-06 Allergan, Inc. Efficient lipid delivery to human tear film using a salt-sensitive emulsion system
ES2706535T3 (en) 2016-07-07 2019-03-29 Salvat Lab Sa Ophthalmic compositions comprising castor oil and medium chain triglycerides
EP3500344A4 (en) 2016-08-19 2020-08-05 Akrivista, LLC METHOD OF DIAGNOSIS AND TREATMENT OF DRY EYE SYNDROME AND COMPOSITIONS FOR TREATMENT OF A HUMAN EYE
BR112020003276A2 (en) 2017-08-18 2020-09-01 Akrivista, LLC methods of diagnosis and treatment of dry eye syndrome and compositions for treating a human eye
AU2019261437B2 (en) 2018-04-27 2024-11-07 Allergan, Inc. Sodium chlorite compositions with enhanced anti-microbial efficacy and reduced toxicity
WO2025175150A1 (en) * 2024-02-16 2025-08-21 Allergan, Inc. Enhanced artificial tear formulations

Family Cites Families (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4201706A (en) 1978-09-22 1980-05-06 Burton, Parsons & Company, Inc. Treatment of corneal edema
EP0028110B1 (en) 1979-10-26 1984-03-07 Smith and Nephew Associated Companies p.l.c. Autoclavable emulsions
US5192535A (en) 1988-02-08 1993-03-09 Insite Vision Incorporated Ophthalmic suspensions
IT1224795B (en) 1988-12-01 1990-10-24 Sigma Tau Ind Farmaceuti USE OF ACETYL D-CARNITINE IN THE THERAPEUTIC TREATMENT OF GLAUCOMA AND PHARMACEUTICAL COMPOSITIONS USEFUL IN SUCH TREATMENT
WO1991001718A1 (en) 1989-08-03 1991-02-21 Eisai Co., Ltd. Method of photostabilizing eyewash and photostabilized eyewash
US5681555A (en) 1991-04-22 1997-10-28 Gleich; Gerald J. Method for the treatment of bronchial asthma by parenteral administration of anionic polymers
DE4229494A1 (en) 1992-09-04 1994-03-10 Basotherm Gmbh Medicines for topical use on the eye to treat increased intraocular pressure
AU3484895A (en) 1994-09-14 1996-03-29 Taisho Pharmaceutical Co., Ltd. Eye drops for repairing corneal disturbance
US5980865A (en) 1995-08-18 1999-11-09 Baker Norton Pharmaceuticals, Inc. Method for treating late phase allergic reactions and inflammatory diseases
FI106923B (en) 1997-01-03 2001-05-15 Cultor Ltd Finnsugar Bioproduc Use of trimethylglycine in preparations for hygiene and care of the mucous membranes of the body
AR002194A1 (en) 1997-03-17 1998-01-07 Sanchez Reynaldo Alemany COMPUTERIZED INSTRUMENT FOR THE ANALYSIS OF MOVEMENT.
IT1302307B1 (en) 1998-09-01 2000-09-05 Sigma Tau Healthscience Spa COMPOSITION WITH ANTIOXIDANT ACTIVITY AND FOR IMPROVING THE METABOLIC USE OF GLUCOSE, INCLUDING ACETYL
US6585987B1 (en) 1998-11-13 2003-07-01 Continental Projects Limited Complexes of hyaluronic acid/carnitines and pharmaceutical and cosmetic compositions
JP2000159659A (en) * 1998-11-30 2000-06-13 Kazuo Tsubota Ophthalmic artificial tears
US6228392B1 (en) 1999-04-29 2001-05-08 Gene Tools, Llc Osmotic delivery composition, solution, and method
KR20030023700A (en) 2000-07-14 2003-03-19 알러간, 인코포레이티드 Compositions containing therapeutically active components having enhanced solubility
CA2355814C (en) 2000-09-14 2010-06-29 Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo Pharmaceutical composition for ophthalmic use
EP1339418B1 (en) 2000-11-08 2009-09-23 FXS Ventures, LLC Improved ophthalmic and contact lens solutions containing simple saccharides as preservative enhancers
US7045121B2 (en) 2001-12-14 2006-05-16 Allergan, Inc. Ophthalmic compositions for lubricating eyes and methods for making and using same
JP2006504701A (en) 2002-09-30 2006-02-09 マーク・エー・バビザイェフ Method for local treatment of eye diseases, therapeutic composition and therapeutic means thereof
US7758883B2 (en) * 2002-10-18 2010-07-20 Aqueous Pharma Limited Three layer artificial tear formulation
US20040137079A1 (en) 2003-01-08 2004-07-15 Cook James N. Contact lens and eye drop rewetter compositions and methods
US6635654B1 (en) * 2003-01-09 2003-10-21 Allergan, Inc. Ophthalmic compositions containing loratadine
US20040185068A1 (en) * 2003-03-18 2004-09-23 Zhi-Jian Yu Self-emulsifying compositions, methods of use and preparation
WO2004084877A1 (en) 2003-03-26 2004-10-07 Menicon Co., Ltd. Composition for ophthalmic use
TWI336257B (en) * 2003-06-13 2011-01-21 Alcon Inc Ophthalmic compositions containing a synergistic combination of three polymers
CN100475192C (en) * 2003-06-13 2009-04-08 爱尔康公司 Ophthalmic compositions containing a synergistic combination of two polymers
US20050009836A1 (en) 2003-06-26 2005-01-13 Laskar Paul A. Ophthalmic composition containing quinolones and method of use
CN1878571B (en) * 2003-11-10 2010-09-08 东丽株式会社 Polysaccharide-containing composition and tear layer stabilizing eye drops
US8569367B2 (en) 2004-11-16 2013-10-29 Allergan, Inc. Ophthalmic compositions and methods for treating eyes
US7288520B2 (en) * 2005-07-13 2007-10-30 Allergan, Inc. Cyclosporin compositions
US7501393B2 (en) * 2005-07-27 2009-03-10 Allergan, Inc. Pharmaceutical compositions comprising cyclosporins
US9561178B2 (en) * 2006-07-25 2017-02-07 Allergan, Inc. Cyclosporin compositions
WO2008035246A2 (en) * 2006-07-28 2008-03-27 Novagali Pharma Sa Compositions containing quaternary ammonium compounds
CN101896160A (en) * 2006-10-17 2010-11-24 阿勒根公司 Cyclosporin composition
CN101668511A (en) * 2007-02-28 2010-03-10 阿西克斯医疗公司 methods and compositions for normalizing meibomian gland secretions
JP4929245B2 (en) 2008-07-31 2012-05-09 株式会社ベッセル工業 Tool grip
HRP20171691T1 (en) * 2009-06-05 2017-12-15 Allergan, Inc. Artificial tears and therapeutic uses
WO2013049621A1 (en) * 2011-09-29 2013-04-04 The Board Of Regents Of The University Of Oklahoma Ophthalmic compositions comprising ppar-alpha agonists and methods of production and use thereof
US8957048B2 (en) * 2011-10-06 2015-02-17 Allergan, Inc. Compositions for the treatment of dry eye

Also Published As

Publication number Publication date
KR102017922B1 (en) 2019-09-03
BR112014013820A8 (en) 2017-06-13
SI2787968T1 (en) 2020-08-31
AU2012347459A1 (en) 2014-07-03
CA2858574C (en) 2017-05-30
US20130150324A1 (en) 2013-06-13
IL233008A (en) 2017-07-31
HK1203057A1 (en) 2015-10-16
AR089123A1 (en) 2014-07-30
WO2013086438A1 (en) 2013-06-13
PH12014501296B1 (en) 2023-04-05
MY173378A (en) 2020-01-21
CN104114152A (en) 2014-10-22
ZA201404228B (en) 2015-12-23
PL2787968T3 (en) 2020-08-24
ES2797650T3 (en) 2020-12-03
DK2787968T3 (en) 2020-06-02
KR20140107383A (en) 2014-09-04
US9314528B2 (en) 2016-04-19
PL2787969T3 (en) 2021-12-20
EP4403220A3 (en) 2024-10-23
CA2858574A1 (en) 2013-06-13
HUE049489T2 (en) 2020-09-28
EP3666257A1 (en) 2020-06-17
RU2018119362A (en) 2018-11-08
MX355216B (en) 2018-04-10
PH12014501296A1 (en) 2014-10-08
ES2896336T3 (en) 2022-02-24
AU2017265181B2 (en) 2019-06-20
JP2015504860A (en) 2015-02-16
DK2787969T3 (en) 2021-11-01
SG11201403013VA (en) 2014-07-30
SI2787969T1 (en) 2021-12-31
EP2787968B1 (en) 2020-03-04
EP2787969B1 (en) 2021-09-29
EP2787969A1 (en) 2014-10-15
MX2014006804A (en) 2014-09-22
EP4403220A2 (en) 2024-07-24
RU2018119362A3 (en) 2021-09-07
EP3981387A1 (en) 2022-04-13
CL2014001518A1 (en) 2014-10-24
PT2787968T (en) 2020-06-16
US20130197083A1 (en) 2013-08-01
EP2787968A1 (en) 2014-10-15
HUE057140T2 (en) 2022-04-28
IL233008A0 (en) 2014-07-31
PH12021553172A1 (en) 2024-05-27
CO6990739A2 (en) 2014-07-10
RU2014127074A (en) 2016-02-10
HK1201458A1 (en) 2015-09-04
TW201325633A (en) 2013-07-01
WO2013086449A1 (en) 2013-06-13
JP6142419B2 (en) 2017-06-07
BR112014013820A2 (en) 2017-06-13
AU2017265181A1 (en) 2017-12-14
TWI652072B (en) 2019-03-01
CN108969482A (en) 2018-12-11
PT2787969T (en) 2021-11-09

Similar Documents

Publication Publication Date Title
MY171920A (en) Prevention and treatment of ocular conditions
IL260585B (en) Preparations and methods for the treatment of diseases related to the retina of the eye
PH12019501902A1 (en) Ocular formulations for drug-delivery to the posterior segment of the eye
IN2014CN04809A (en)
HRP20130830T1 (en) A water-in-oil type emulsion for treating a disease of the eye
MX362185B (en) Compositions and treatment for eye diseases and disorders.
UA114705C2 (en) ANDROGENIC COMPOSITION FOR THE TREATMENT OF OPHTHALMOLOGICAL DISEASE
IN2014CN03123A (en)
IL239478B (en) Preparations for the treatment or prevention of dry eye
PH12014500179A1 (en) Fixed dose combination of bimatoprost and brimonidine
HUE051295T2 (en) Modified fibroblast growth factors-1 for the treatment of eye diseases
EP3013425A4 (en) Treatment and diagnosis of ocular disease
IN2015DN02501A (en)
UY34843A (en) TREATMENT OF OCULAR INFLAMMATORY DISEASES USING LAQUINIMOD
MX2016005505A (en) Cetp modulator for use in the treatment of eye disease.
EP3145532A4 (en) Individualized treatment of eye disease
EP3182952A4 (en) Modifying humidity to glabrous tissue for the treatment of migraine and other conditions
PH12015501211A1 (en) Use of pidotimod to treat atopic dermatitis
EP2962691A4 (en) Agent for preventing or treating diseases of posterior part of the eye and containing tetrahydropyranyl amino cyclopentylcarbonyl tetrahydropyridopyridine derivative as active component
UA113065C2 (en) SKIN COMPOSITION AND APPLICATION
HK40043513B (en) Interval therapy for the treatment of eye diseases
UA111645C2 (en) EFFICIENT DELIVERY OF LIPIDES INTO THE TREATMENT OF HUMAN FILM USING THE SALT-EMULSIVE SYSTEM
PL401911A1 (en) Use of the preparation with the immunoregulatory properties
MX2013006527A (en) Arylsulfonamide derivatives for the prevention or treatment of specific ophthalmologic disorders.
CN302327175S (en) glasses